Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- AstraZeneca
- Azonosító
- NCT07933510
- A regiszteradat frissítve
- 2026. november 12.
- Eredeti leírás
This is a single arm, prospective non-interventional study with primary data collection in patients initiated BGF MDI treatment as part of routine clinical care. In this study, 200 patients will be enrolled from approximately 20 sites mainly in general hospitals with respiratory/allergy/asthma specialists in Japan.A teljes eredeti leírásKevesebb
BENTEN Study: Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI): a Prospective, Multi-centers, Observational Study
This is a single arm, prospective non-interventional study with primary data collection in patients initiated BGF MDI treatment as part of routine clinical care. In this study, 200 patients will be enrolled from approximately 20 sites mainly in general hospitals with respiratory/allergy/asthma specialists in Japan.
Bevonási feltételek: Patients aged >=18 years at enrollment; Patients diagnosed with asthma with an ACQ -5 score ≥1.5 at enrollment; Patients who are judged to newly initiate BGF MDI (320/28.8/9.6 ug) treatment as per the investigator's decision and are able to initiate inhalation on the same day as the prescription or, if they have already used another inhaled medication on that day, on the following day; Patients who are capable to fill PRO physically and mentally as judged by investigator; Patients who are assessed as able to visit the study site during the 8-week follow-up period; Patients who provide written informed consent.
Kizáró feltételek: Patients who have been treated with ICS/LABA/LAMA within 6 months before enrollment; Patients who have history of asthma exacerbation within 4 weeks before enrollment; Patients who have history of respiratory infection within 4 weeks before enrollment; Patients who are prescribed systemic corticosteroids within 4 weeks before enrollment; Patients who have been treated with any biologic therapy for asthma (e.g., anti-IgE, anti-IL-5/IL-5R, anti-IL-4R, anti-TSLP) within 1 year before enrollment; Patients who have participated in any interventional studies within 1 year before enrollment; Patients who are pregnant, lactating or intending to become pregnant during the study period.